Search results
Author(s):
Wouter Jacobs
,
Anton Vonk-Noordegraaf
Added:
3 years ago
Abstract
Pulmonary arterial hypertension is a progressive disease of the pulmonary vasculature, ultimately leading to right heart failure and death. Current treatment is aimed at targeting three different pathways: the prostacyclin, endothelin and nitric oxide pathways. These therapies improve functional class, increase exercise capacity and improve haemodynamics. In addition, data from a meta…
View more
Author(s):
Eva Goncalvesova
Added:
3 years ago
Abstract
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease with poor prognosis and limited therapeutic options. While currently available PAH treatments can provide substantial clinical benefits, they are not curative. The efficacy of prostanoid treatment in PAH is well-established in clinical trials, open-label and long-term observational studies, and prostanoid…
View more
Author(s):
Carmine Dario Vizza
,
Roberto Badagliacca
,
Roberto Poscia
,
et al
Added:
3 years ago
Abstract
Pulmonary arterial hypertension (PAH) is a serious and life-threatening condition for which the prognosis remains poor. Treatment options include endothelial receptor antagonists, phosphodiesterase (PDE5) inhibitors and prostanoids. Despite all demonstrating good short-term efficacy, none of the currently available drug therapies are curative. Treatment with prostanoids is complex and…
View more
Author(s):
Natalie Koh
,
Brian Ference
,
Stephen J Nicholls
,
et al
Added:
2 years ago
Author(s):
Athanasios Charalampopoulos
,
J Simon R Gibbs
Added:
3 years ago
Abstract
Pulmonary hypertension is a relatively common finding in patients with left heart disease and lung hypoxic disease. Nonetheless, some types of pulmonary hypertension, such as pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, are rare. Despite the rarity of these diseases their impact on patients' lives and healthcare system is significant because of…
View more
Author(s):
Harriette Van Spall
,
Adriaan A Voors
Added:
2 years ago
In this in-depth conversational interview, Late-breaker host Dr Harriette Van Spall (McMaster University, CA) meets PI, Prof Adriaan Voors (University Medical Center Groningen, NL) to discuss the EMPULSE trial. The aim of the trial was to evaluate empagliflozin compared with placebo among patients with acute decompensated heart failure.
Presented first at AHA 2021, the trial showed that that…
View more
AHA 2021: Late-breaking Science Video Collection
Author(s):
Anushka Patel
,
Stephen Nicholls
,
Jeffrey Weitz
,
et al
Added:
2 years ago
Video Series
Author(s):
Vincent Floré
,
Rik Willems
Added:
3 years ago
Sudden cardiac arrest (SCA) can be defined as the abrupt cessation of cardiac activity due to an underlying cardiac cause, occurring instantaneously in a previously stable patient and in the absence of non-cardiovascular causes (e.g., trauma, intoxication, drowning, electrocution).1,2 SCA will lead to loss of consciousness within the minute due to insufficient cerebral perfusion. If no immediate…
View more
Author(s):
Joost Daemen
,
Nicolas M Van Mieghem
Added:
5 months ago
What's hot at TCT 2023?
In this episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the late-breaking data presented at TCT 2023.
With their dynamic analysis, these anticipated trials are placed in context, highlighting the real-world implications tied to the data releases.
Top trials covered:
00:31 - 02:12: PARTNER 3 Low…
View more
Author(s):
Zaki Akhtar
,
Lisa WM Leung
,
Christos Kontogiannis
,
et al
Added:
2 years ago